616865-28-2
616865-28-2
Chemical Structure
Chlorzoxazone-13C
- CAS No.: 616865-28-2
- Formula:C613CH4ClNO2
- Molecular Weight:170.56
IUPAC Name: 5-chlorobenzo[d]oxazol-2(3H)-one-2-13C
InChIKey: TZFWDZFKRBELIQ-CDYZYAPPSA-N
SMILES: O=[13C]1OC2=CC=C(Cl)C=C2N1
Biological Activity: Chlorzoxazone-13C is the 13C labeled Chlorzoxazone[1]. Chlorzoxazone is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort[2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Chlorzoxazone-13C | Chlorzoxazone-13C is the 13C labeled Chlorzoxazone. Chlorzoxazone is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Chlorzoxazone (Standard) | 99.81% | Chlorzoxazone (Standard) is the analytical standard of Chlorzoxazone. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Chlorzoxazone-13C,15N,d2 | Chlorzoxazone-13C,15N,d2 is 13C-, 15N-, and deuterium-labeled Chlorzoxazone (HY-B1462). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Chlorzoxazone-d3 | 99.88% | Chlorzoxazone-d3 is the deuterium labeled Chlorzoxazone. Chlorzoxazone is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort. It acts on the spinal cord by depressing reflexes.Chlorzoxazone is currently being used as a marker substrate in vitro/vivo studies to quantify cytochrome P450 2E1 (CYP2E1) activity in humans. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Chlorzoxazone | 99.77% | Chlorzoxazone is a SK-type potassium channel activator. Chlorzoxazone modulates FOXO3 phosphorylation and Aβ. Chlorzoxazone enhances immunosuppression, attenuates vasoconstriction, attenuates cognitive deficits, and improves experimental autoimmune encephalomyelitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Yamamura Y, et al. Comprehensive kinetic analysis and influence of reaction components for chlorzoxazone 6-hydroxylation in human liver microsomes with CYP antibodies. Xenobiotica. 2015 Apr;45(4):353-360. [Content Brief]
